Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease.
The management of polycystic ovarian disease in women not desiring pregnancy is controversial. To avoid the progressive androgenic effects on peripheral target organs, some advocate the use of oral contraceptives. This study reports the effects of a preparation with 50 micrograms ethinyl estradiol and 2 mg cyproterone acetate on gonadotropins, prolactin, testosterone, sex hormone binding globulin (SHBG), androstenedione, and calculated free testosterone index before and after six months of treatment. Gonadotropins, testosterone, and androstenedione levels decreased, prolactin did not change, and sex hormone binding globulin increased as the result of the treatment. This led to a net decrease in the calculated free testosterone.
D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004997:Ethinyl Estradiol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D010907:Pituitary Hormones / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy
D003278:Contraceptives, Oral, Hormonal; D012739:Gonadal Steroid Hormones; D010907:Pituitary Hormones; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D003534:Cyproterone